We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Heart Transplantation
MedXY News
EnglishTag

Heart Transplantation

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing Donor Heart Preservation: Superior Outcomes with 10°C Versus 4-8°C in Adult Heart Transplantation
CardiologyHeart Transplantationgraft function

Optimizing Donor Heart Preservation: Superior Outcomes with 10°C Versus 4-8°C in Adult Heart Transplantation

By MedXY|Aug 5, 2026

A multicenter study reveals that preserving donor hearts at 10°C results in better early graft function and one-year survival than traditional 4-8°C storage, suggesting a new standard for heart transplant preservation.

Machine-learning model incorporating perioperative hemodynamics predicts moderate-to-severe AKI after heart transplantation
TransplantationHeart Transplantationacute kidney injury

Machine-learning model incorporating perioperative hemodynamics predicts moderate-to-severe AKI after heart transplantation

By MedXY|Jul 29, 2026

A machine-learning model using perioperative hemodynamic indices accurately predicted stage 2-3 acute kidney injury after orthotopic heart transplantation in 114 patients, with light gradient boosting machine achieving AUC 0.898.

Evaluating the Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates on Durable LVAD Support
CardiologyHeart TransplantationLVAD

Evaluating the Impact of the OPTN Status Escalation Policy for Adult Heart Transplant Candidates on Durable LVAD Support

By MedXY|Jun 24, 2026

The OPTN’s new status escalation policy for stable adult heart transplant candidates with durable LVADs may benefit only a small fraction of patients, as most experience complications or transplant within six years.

Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Severe Cardiac Allograft Rejection: From Detection to Risk Stratification
Clinical Updatesdd-cfDNAHeart Transplantation

Donor-Derived Cell-Free DNA as a Prognostic Biomarker in Severe Cardiac Allograft Rejection: From Detection to Risk Stratification

By MedXY|Jun 17, 2026

Recent heart-transplant studies show donor-derived cell-free DNA not only detects rejection but also predicts mortality and persistent graft dysfunction, especially when elevated at diagnosis. Evidence supports a shift from binary surveilla

A Mobility-Enabled Active Driver for Berlin Heart EXCOR Showed Zero Major Device Malfunctions in High-Risk Pediatric VAD Support
CardiologyBerlin Heart EXCORDevice Safety

A Mobility-Enabled Active Driver for Berlin Heart EXCOR Showed Zero Major Device Malfunctions in High-Risk Pediatric VAD Support

By MedXY|Jun 10, 2026

In a prospective multicenter study, the EXCOR Active Driver demonstrated excellent reliability and high short-term survival in children requiring ventricular assist support, while supporting a registry-enabled pathway for class III pediatri

Circulating MicroRNA Scores May Distinguish Cellular and Antibody-Mediated Heart Transplant Rejection With High Accuracy
Cardiologyacute cellular rejectionantibody-mediated rejection

Circulating MicroRNA Scores May Distinguish Cellular and Antibody-Mediated Heart Transplant Rejection With High Accuracy

By MedXY|May 25, 2026

A prospective multicenter study found circulating microRNA rejection scores identified ACR and AMR with strong diagnostic performance and prognostic value, supporting their development as noninvasive tools to reduce reliance on surveillance

Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation
CardiologyCardiologyHeart Transplantation

Misaligned Urgency: Why Status Exceptions May Be Paradoxically Lowering Priority for the Sickest Children in Heart Transplantation

By MedXY|Mar 10, 2026

A large-scale analysis of 6,026 pediatric heart transplant candidates reveals that status exceptions often prioritize patients with lower mortality risk than those meeting standard criteria, highlighting a significant misalignment in the U.

Molecular Profiling of Formalin-Fixed Biopsies: A Paradigm Shift in Diagnosing Heart Allograft Rejection
CardiologyHeart Transplantation

Molecular Profiling of Formalin-Fixed Biopsies: A Paradigm Shift in Diagnosing Heart Allograft Rejection

By MedXY|Jan 5, 2026

A landmark study validates the first FFPE-based molecular diagnostic system for heart transplant rejection, demonstrating high accuracy in identifying antibody-mediated and cellular rejection through targeted gene expression profiling acros

The LVAD Paradox in Heart Transplantation: Higher Risk of Primary Graft Dysfunction, Yet Improved Survival Outcomesdszcx
CardiologyHeart Transplantationhemodynamics

The LVAD Paradox in Heart Transplantation: Higher Risk of Primary Graft Dysfunction, Yet Improved Survival Outcomesdszcx

By MedXY|Dec 29, 2025

A large-scale multicenter study reveals that while pre-transplant durable LVAD support increases the incidence of severe primary graft dysfunction (PGD), these patients paradoxically demonstrate significantly better survival rates compared

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks
CardiologyHeart TransplantationHội Chứng CKM

Post-Heart Transplantation Survival Comes with a Heavy Cardiovascular-Kidney-Metabolic Burden: New Data on DM2 and CKD Risks

By MedXY|Dec 29, 2025

A longitudinal study of 944 heart transplant recipients reveals a staggering incidence of metabolic and renal dysfunction. While diabetes significantly increases mortality risk, the study highlights the potential of SGLT2 inhibitors and GLP

Aggressive LDL-C Lowering Post-Heart Transplant: Why Alirocumab Didn’t Halt Early Vasculopathy in the CAVIAR Trial
CardiologyAlirocumabCardiac Allograft Vasculopathy

Aggressive LDL-C Lowering Post-Heart Transplant: Why Alirocumab Didn’t Halt Early Vasculopathy in the CAVIAR Trial

By MedXY|Dec 25, 2025

The CAVIAR trial reveals that while alirocumab significantly reduces LDL-C in heart transplant recipients, it does not arrest coronary plaque progression within the first year, suggesting that early cardiac allograft vasculopathy may be dri

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities